IP Library › Granted Patent US 12,024,544
Granted Patent B2
US 12,024,544 · App. 17/991,219 · Granted Jul 2, 2024

CCN3 and CCN3 peptides and analogs thereof for therapeutic use

Inventor: Bruce L. Riser (Kenosha, WI)
Assignee: Rosalind Franklin University of Medicine and Science
C07K14/47A61K9/0014A61K35/12A61K35/28A61K35/51A61K38/04A61K38/10A61K38/1709C07K14/4743C07K14/475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,024,544
App. No.
17/991,219
Granted
Jul 2, 2024
Kind
B2
Abstract

The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

Claims (2)

1. A peptide comprising a sequence selected from the group consisting of SEQ ID NOs: 39, 40, 59, 60, 61, and 62.

2. A peptide comprising a sequence selected from the group consisting of SEQ ID NOs: 36-40, 42, 53-62, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2022
From: RISER, BRUCE L.
To: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
Reel/Frame 061842/0106 →
Continuity (6)
Continuation 16511103 · Jul 15, 2019
Continuation 14821494 · Aug 7, 2015
Division 13725658 · Dec 21, 2012
Continuation In Part 13079693 · Apr 4, 2011
Provisional Application 61341694 · Apr 2, 2010
Related Publication 20230272021A1 · Aug 31, 2023